Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial
about
Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problemRole of estrogen in diastolic dysfunctionClinical Phenotypes in Heart Failure With Preserved Ejection FractionObesity paradox in heart failure: a heavy matter.A U-shaped association of body mass index and all-cause mortality in heart failure patients: A dose-response meta-analysis of prospective cohort studies.Mortality after total hip replacement surgery: A systematic review.Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary studyTen-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study.Depressive symptoms and the relationship of inflammation to physical signs and symptoms in heart failure patients.New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.Noncardiac comorbidities in heart failure with reduced versus preserved ejection fractionPsychometric properties of the Symptom Status Questionnaire-Heart Failure.Burden of Comorbidities and Functional and Cognitive Impairments in Elderly Patients at the Initial Diagnosis of Heart Failure and Their Impact on Total Mortality: The Cardiovascular Health Study.Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue.Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.Sarcopenic obesity and the pathogenesis of exercise intolerance in heart failure with preserved ejection fraction.Predictors of new-onset heart failure: differences in preserved versus reduced ejection fractionPhenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study.Frailty and multiple comorbidities in the elderly patient with heart failure: implications for management.Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults.Diastolic heart failure: the current understanding and approach for management with focus on intensive care unit patients.How do patients with heart failure with preserved ejection fraction die?Biomarkers of heart failure with normal ejection fraction: a systematic review.Risk Factors for Incident Hospitalized Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Postmenopausal WomenThe potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management.Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use.Association between obesity and heart failure symptoms in male and female patients.New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations.No benefit from the obesity paradox for diabetic patients with heart failure.Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction.Skeletal Muscle Mitochondrial Content, Oxidative Capacity, and Mfn2 Expression Are Reduced in Older Patients With Heart Failure and Preserved Ejection Fraction and Are Related to Exercise Intolerance.Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction?Impact of overweight on left ventricular function in type 2 diabetes mellitus.Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus.Effect of bariatric surgery on heart failure.Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition".Impact of Body Mass Index on Heart Failure by Race/Ethnicity From Get With The Guidelines-Heart Failure (GWTG-HF) Registry.Coronary Microvascular Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction.
P2860
Q26991985-43FFE60F-B240-4F89-A6DA-7C3FC4576D1AQ27026798-2F650370-EB0B-4BF3-AF14-B167B64890C9Q28073079-16FB2008-B05F-4BE2-80CD-962A30CB6A3BQ28074729-4B152D4F-452A-4D4C-ADC7-F51F7353F5AEQ30244073-C6645E8E-3A70-47A7-A315-AF0674A44D10Q33742808-6FB9A1C3-CAE3-49D4-9361-6532142CE597Q33992679-BE1EFF08-407A-422E-99AB-EC0B36902E8EQ34130091-9C2575AA-7C16-4DD1-A186-207E2AF499B5Q34139572-AF024B85-19D1-4113-B86D-70D82F640E51Q34375466-EE034FCA-2480-44F4-A880-553E58692D78Q34625223-9E2E3786-8CDB-49ED-8C03-284C4CF7C3F5Q35345339-B16C35C9-285B-4B92-896E-608432E95AD7Q35842447-33DA53B8-1FA6-424D-BF36-1C1899211F7AQ35882942-B00B5E46-14EB-4DB2-A843-8ECBF5658EDCQ36303452-7EE7BE3A-EF97-4644-9045-C16091BC1FFEQ36676033-12897854-8944-4DEE-9957-2D8790FB23D7Q36683918-CED8E943-6CE4-410C-93F7-416C4894EBC2Q36993734-A25B3458-E765-4269-8F3A-177CFFFBB2B0Q37058596-5D7719F3-7350-49CB-8C7C-6D1BC3D4FDD9Q37156991-2CC3D2F2-BF08-41A9-9170-F20971B095F3Q37245614-D0A833A9-4032-43A5-9A02-CC87ADB4697CQ37993133-E9EDFAAC-8A64-4217-9714-A573B10A1C9AQ38025610-C84B2FDA-5DA4-412E-8235-2339F09E7AF8Q38101027-057C682E-3533-43C2-880F-DB693177D021Q38120919-83D133D5-4B5B-469D-9DE6-A3921AC25372Q38387058-253D1163-409B-4CBB-BE3B-620509F35312Q38551693-D9BAFD61-43E2-48C7-8090-E8ECA7E59D95Q38614176-8A714CB5-19F4-40DA-9BAF-17AC38C0BCF2Q39002034-0FDC3411-4DE2-45D8-BAA9-5644D24972A6Q39218629-A0F97E5F-A428-4BB6-B870-4438E1A44D37Q40696102-AE335DBF-56FC-4809-A71A-6E0A0571F372Q41025346-AFB15C51-047C-404E-BE82-4FD60A2CEBEFQ42062803-FBC3B391-2934-4251-94DF-7D6B1A913495Q46466507-3E54152C-5C33-4AB9-A7EA-5433DB69979DQ47146474-7C36F2BB-C3C9-45E1-9FB1-E03D5C982948Q47734427-C02638D8-A0C5-4037-8AF3-74FBE357C34EQ48116252-FDBB38BD-8E9B-4EA0-AB01-BABBABD55BF6Q49203906-B866A060-C6A9-46DA-AE30-4BAF517A4E80Q50083097-596928AB-CBF9-477F-A3CB-BD9AACE6B4D6Q50101993-AA2A2A4E-5D48-410D-8DCA-9348610D5DA6
P2860
Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Body mass index and adverse ca ...... on Fraction (I-PRESERVE) trial
@ast
Body mass index and adverse ca ...... on Fraction (I-PRESERVE) trial
@en
Body mass index and adverse ca ...... th Preserved Ejection Fraction
@nl
type
label
Body mass index and adverse ca ...... on Fraction (I-PRESERVE) trial
@ast
Body mass index and adverse ca ...... on Fraction (I-PRESERVE) trial
@en
Body mass index and adverse ca ...... th Preserved Ejection Fraction
@nl
prefLabel
Body mass index and adverse ca ...... on Fraction (I-PRESERVE) trial
@ast
Body mass index and adverse ca ...... on Fraction (I-PRESERVE) trial
@en
Body mass index and adverse ca ...... th Preserved Ejection Fraction
@nl
P2093
P2860
P921
P1476
Body mass index and adverse ca ...... on Fraction (I-PRESERVE) trial
@en
P2093
Alan Miller
Barry M Massie
Dalane W Kitzman
Inder S Anand
Markus Haass
Michael R Zile
Peter E Carson
P2860
P304
P356
10.1161/CIRCHEARTFAILURE.110.959890
P577
2011-02-24T00:00:00Z